1,000 Shares in Cidara Therapeutics, Inc. $CDTX Bought by Trifecta Capital Advisors LLC

Trifecta Capital Advisors LLC acquired a new position in shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 1,000 shares of the biotechnology company’s stock, valued at approximately $49,000.

Other hedge funds have also recently bought and sold shares of the company. American Century Companies Inc. bought a new stake in Cidara Therapeutics in the 1st quarter valued at $224,000. West Michigan Advisors LLC bought a new stake in Cidara Therapeutics in the 1st quarter valued at $291,000. OMERS ADMINISTRATION Corp boosted its holdings in Cidara Therapeutics by 53.2% in the 1st quarter. OMERS ADMINISTRATION Corp now owns 19,300 shares of the biotechnology company’s stock valued at $416,000 after purchasing an additional 6,700 shares during the period. Jane Street Group LLC boosted its holdings in Cidara Therapeutics by 119.0% in the 1st quarter. Jane Street Group LLC now owns 27,849 shares of the biotechnology company’s stock valued at $600,000 after purchasing an additional 15,135 shares during the period. Finally, Goldman Sachs Group Inc. boosted its holdings in Cidara Therapeutics by 203.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 42,143 shares of the biotechnology company’s stock valued at $908,000 after purchasing an additional 28,273 shares during the period. 35.82% of the stock is owned by institutional investors.

Insider Activity at Cidara Therapeutics

In other news, insider Nicole Negar Davarpanah sold 474 shares of Cidara Therapeutics stock in a transaction that occurred on Thursday, September 11th. The shares were sold at an average price of $62.86, for a total transaction of $29,795.64. Following the completion of the sale, the insider owned 31,418 shares in the company, valued at $1,974,935.48. The trade was a 1.49% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 3.89% of the stock is currently owned by corporate insiders.

Cidara Therapeutics Trading Down 3.6%

CDTX opened at $98.51 on Thursday. The stock has a market capitalization of $2.50 billion, a PE ratio of -8.85 and a beta of 1.33. Cidara Therapeutics, Inc. has a 1-year low of $10.14 and a 1-year high of $106.63. The firm has a 50-day moving average price of $71.54 and a two-hundred day moving average price of $44.91.

Cidara Therapeutics (NASDAQ:CDTX) last posted its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($1.65) earnings per share for the quarter, beating the consensus estimate of ($1.87) by $0.22. On average, research analysts predict that Cidara Therapeutics, Inc. will post -8.74 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. JMP Securities set a $173.00 price objective on shares of Cidara Therapeutics and gave the stock a “market outperform” rating in a report on Friday, October 3rd. HC Wainwright raised their price objective on shares of Cidara Therapeutics from $74.00 to $110.00 and gave the stock a “buy” rating in a report on Friday, September 26th. Citigroup reaffirmed an “outperform” rating on shares of Cidara Therapeutics in a report on Wednesday, September 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cidara Therapeutics in a report on Wednesday. Finally, Royal Bank Of Canada set a $137.00 price target on shares of Cidara Therapeutics and gave the company an “outperform” rating in a report on Wednesday, September 24th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $122.29.

Cidara Therapeutics Company Profile

Cidara Therapeutics, Inc, a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.